ESMO 2022: Highlights, commentary and analysis

Bookmark and Share
Published: 12 Sep 2022
Views: 965
Dr Bishal Gyawali - Queen's University, Kingston, Canada

Dr Bishal Gyawali casts his ascerbic eye over the key studies from ESMO 2022.

Starting with a commentary on the difficulties of oncologists from LMICs attending such meetings, he goes on to cover both the early cancer setting and de-escalation of treatment.

He covers the following studies:


CANOPY-A: Phase III study of canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer
Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention
IMmotion010: Efficacy and safety from the phase III study of atezolizumab vs placebo as adjuvant therapy in patients with renal cell carcinoma at increased risk 5878 of recurrence after resection
Phase III randomized study comparing perioperative 5989 nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial
Adjuvant nivolumab plus ipilimumab vs placebo for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial
Primary results of the phase III KEYNOTE-412 study: Pembrolizumab with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)
Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
Nivolumab plus ipilimumab 6-months treatment versus continuation in patients with advanced non-small cell lung cancer: Results of the randomized IFCT-1701 phase III trial
Comparison of abiraterone acetate and prednisolone or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer starting androgen deprivation therapy: Overall survival results of 2 randomised phase III trials from the STAMPEDE protocol in prostate ADT therapy
Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): a randomised phase 3 study
FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group
Pancreatic cancer trial - Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study
Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma
Camrelizumab plus rivoceranib vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma: A randomized, phase III trial
Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumours
Treatment with tumour-infiltrating lymphocytes versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial


Dr Gyawali’s thoughts on the latest breast and ovarian data will be coming soon in a second video.